Ario Pharma acquires PharmEste’s TRPA1 research assets
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
List view / Grid view
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
12 June 2014 | By AstraZeneca
AstraZeneca announced a global licence agreement with Synairgen Plc for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma...